Please ensure Javascript is enabled for purposes of website accessibility

Baxter International Inc.'s Cost-Cutting Efforts Pay Off in the Third Quarter

By Keith Speights - Oct 25, 2017 at 1:17PM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

The medical supply company notches solid revenue and earnings gains but warns that fourth-quarter sales could be hurt by the impact of Hurricane Maria.

When Baxter International (BAX -2.40%) reported quarterly results in July, there was a stark contrast between the company's top and bottom lines. Revenue growth was essentially flat, but the medical products supplier posted strong adjusted earnings growth thanks to operational efficiencies.

Sales must grow at some point for a company to be successful, though. Baxter announced its third-quarter results before the market opened on Wednesday. This time, the company did achieve better revenue growth, but the main story once again was on Baxter's tight control of costs. Here are the highlights.

Red third quarter button on keyboard

Image source: Getty Images.

Baxter results: The raw numbers

Metric 

Q3 2017 

Q3 2016 

Year-Over-Year Change

Sales

 $2.71 billion  $2.56 billion

5.8%

Net income from continuing operations

 $251 million  $130 million

93.1%

Earnings per share (EPS)

$0.45 $0.23

95.7%

Adjusted EPS

 $0.64  $0.60

6.7%

Data source: Baxter International. 

What happened with Baxter this quarter?

Sales increased by nearly 6% year over year in the third quarter for Baxter, although that wasn't all organic growth. Baxter acquired Claris Injectables on July 27, 2017. This acquisition added roughly $27 million in revenue from injectable pharmaceuticals. 

Still, Baxter managed to overcome headwinds, including generic competition in the U.S. for its cyclophosphamide chemotherapy. While the company made more money in international markets (around $1.6 billion), Baxter grew sales somewhat faster in the U.S., where it made $1.1 billion.

Hospital products continued to be the biggest winner for Baxter, with revenue increasing 7% year over year to $1.7 billion. There were several factors behind this growth, including strength for the U.S. fluid systems business, anesthesia and critical care products, hospital pharmacy compounding services, and the Claris Injectables acquisition. Baxter's renal business posted revenue of $1 billion, up 3% from the prior-year period. 

Baxter's tremendous improvement in earnings stemmed yet again from belt-tightening. The company cut its marketing and administrative expenses to $685 million, down 6% from the same quarter of 2016. Baxter also reduced research and development spending by 5% year over year to $151 million. 

Prior-year-period comparisons, however, were skewed by large special items in the third quarter of 2016. The most significant of these was a $325 million charge in the year-ago period for restructuring-related expenses. Adjusting for these costs brought Baxter year-over-year adjusted earnings-per-share growth more in line with its revenue growth. However, the company still topped its previous guidance for the third quarter of adjusted earnings between $0.58 and $0.60 per diluted shared.

What management had to say

Baxter International chairman and CEO Jose (Joe) Almeida highlighted the company's efforts in controlling costs. Almeida said:

Baxter's solid performance in the third quarter reflects our continued focus on disciplined execution. We are advancing innovation and operational excellence across the organization to deliver positive results for our stakeholders -- even as we respond to extraordinary challenges like the recent natural disasters across the Americas and the Caribbean. I'm proud of how our employees continuously step up to make a difference for our patients, healthcare providers, global communities and fellow colleagues.

Looking forward

Baxter has three manufacturing facilities in Puerto Rico. The aftermath of Hurricane Maria, which hit Puerto Rico very hard, will linger for the company. Baxter expects that the temporary manufacturing disruptions will shave around $70 million off its fourth-quarter revenue. However, the company still projects sales growth next quarter between 4% and 5%, with earnings from continuing operations, before special items, of $0.56 to $0.59 per diluted share.

For full-year 2017, Baxter still anticipates sales growth of 4%. The company boosted its adjusted earnings per share outlook for 2017 to between $2.40 and $2.43 per diluted shared. Baxter's previous guidance called for adjusted earnings per share of $2.34 to $2.40.

Baxter won't be able to keep cutting costs indefinitely. Investors will want to watch for the company's efforts in growing revenue. Full integration of Claris Injectables should help. So should launches of new products, such as its three-in-one set for use in continuous renal replacement therapy (CRRT) and sepsis management protocols recently introduced in some international markets. There's also the possibility that Baxter might make additional acquisitions to fuel growth. 

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Baxter International Inc. Stock Quote
Baxter International Inc.
BAX
$64.23 (-2.40%) $-1.58

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning analyst team.

Stock Advisor Returns
317%
 
S&P 500 Returns
112%

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 07/01/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.